SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending within a volatile low-float SPAC sector, fueled by discussions surrounding its extremely tight share float and high insider ownership. The community is actively debating its potential for rapid price movement and a short squeeze, drawing comparisons to other recently surging SPACs as new utility via a planned reward token is also highlighted.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending strongly after securing FDA approval for NEREUS, its motion-sickness treatment, which is seen as the first new pharmacologic option in decades. The community is actively discussing the drug's significant potential in addressing GLP-1 induced nausea, fueling speculation of a major pharmaceutical buyout and leading many to view the stock as currently undervalued. With additional pipeline approvals anticipated, traders are closely watching for sustained momentum as the market fully integrates this landmark development.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently a focal point for year-end tax loss selling, leading to sharp price movements and a polarized community discussion. Many foresee further declines for the meme coin, while a resilient group of long-term holders views the current dip as a strategic accumulation opportunity for future crypto cycles, with eyes on a potential rally in 2026.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending due to a significant price drop following an FDA Complete Response Letter for its relacorilant drug for Cushing syndrome, with the agency requesting additional efficacy evidence. Community discussion is polarized, with some investors calling the sell-off an overreaction given the company's existing profitable drug Korlym and other pipeline assets. The immediate focus is on whether the company can quickly find a path forward with the FDA and if current levels present a "bargain biobuy" or a "falling knife."

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens (XLM) is trending amid a significant price drop, sparking a highly polarized community debate. While many express extreme bearishness, labeling it a "scam" and predicting further declines, a resilient group views current lows as a buying opportunity, citing its ISO compliance, recent network upgrades, and potential for institutional adoption. The broader crypto market sentiment continues to heavily influence discussions around XLM's future trajectory.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome received a regulatory setback from the FDA, which the community views as a significant advantage for Xeris's approved treatment, Recorlev. This development is seen as clearing the path for Recorlev to gain market share, fueling discussions among investors about the company's long-term growth potential and undervaluation, supported by positive analyst outlooks.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin (LTC) is currently trending, fueled by reports highlighting its "digital silver" status and recent outperformance, alongside discussions of an upcoming EzFill integration. The community expresses mixed sentiment, with some frustrated by its price action while many uphold strong long-term bullish convictions for its foundational role. Ongoing anticipation for Grayscale's potential ETF and future growth further drives conversation.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is surging due to recent FDA updates, including priority review acceptance for AXS-05 for Alzheimer's disease agitation and positive pre-NDA meeting minutes supporting an AXS-12 submission for narcolepsy. The community is celebrating these significant advancements, seeing them as key catalysts driving the company toward profitability and anticipating further growth in its CNS portfolio.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the extension of China's NEV trade-in subsidies into 2026 fuels optimism across the sector, coinciding with an upbeat Q4 sales forecast from management suggesting potential profitability. While bulls are aggressively buying recent dips and anticipating a strong year-end, skeptics remain wary of past volatility and alleged market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.4% - Here's Why

Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 3.4% - Time to Sell...

Why Praxis Precision Medicines Stock Popped Today

Key PointsMillions of people suffer from movement disorders...

Top Pharmaceutical Stocks To Research - December 29th

Eli Lilly and Company, Novo Nordisk A/S, Pfizer, Ultragenyx Pharmaceutical, Praxis Precision Medicines, AbbVie, and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according...

Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.read more...

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High - Time to Buy?

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High - What's Next...

<ul class="summary-bullets"><li>The early clinical evidence suggested ulixacaltamide could provide meaningful improvement over current therapies for ET patients.</li><li>The BTD recognizes ulixacaltamide as a potential step-change therapy, offering a more selective inhibition of T-type calcium channels.</li><li>BTIG has raised its price target for Praxis to $843 from $507 per share while maintaining a ‘Buy’ rating.</li></ul>Praxis Precision Medicines, Inc. (PRAX) announced on Monday that it has received a Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for its experimental drug, ulixacaltamide, aimed at treating essential tremor (ET).The early clinical evidence suggested ulixacaltamide could provide meaningful improvement over current therapies for ET patients.<h2 class="st-heading-2">Expedited Regulatory Path</h2>The designation, which speeds up both development and regulatory review for drugs addressing serious conditions, was granted after positive topline results from the Essential3 program, which included two Phase 3 studies of ulixacaltamide.The BTD recognizes ulixacaltamide as a potential step-change therapy, offering a more selective inhibition of T-type calcium channels, a mechanism linked to abnormal neuronal signaling in essential tremor.&nbsp;By targeting this pathway, Praxis aims to rebalance neuronal excitation and inhibition in patients, potentially improving motor function and daily life activities.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/PRAX">Praxis Precision stock</a> traded over 12% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock changed to ‘neutral’ from ‘bearish’ territory the previous day amid ‘extremely low’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:934/96;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_083747_png_00ae2870dd.webp" alt="PRAX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Dec. 29, 2025 | Source: Stocktwits" width="934" height="96"><figcaption>PRAX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Dec. 29, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">BTIG Raises Price Target&nbsp;</h2>BTIG has raised its price target for Praxis to $843 from $507 per share while maintaining a ‘Buy’ rating. The firm cited the company’s upcoming launch of ulixacaltamide as “uniquely advantaged” in the essential tremor (ET) market.BTIG emphasized that Praxis will develop an "unprecedented" database of one million ET patients, potentially supporting swift adoption of ulixacaltamide. The firm also raised its projected U.S. launch price for ulixacaltamide from $14,000 to $36,000, reflecting favorable pricing analogues.PRAX stock has gained over 249% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/after-80-slide-this-year-solidion-draws-a-second-doe-grant-for-advanced-nuclear-tech/cL75tq9RExR">After 80% Slide This Year, Solidion Draws A Second DOE Grant For Advanced Nuclear Tech</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did Praxis Precision Stock Surge 12% Pre-Market Today?

The Breakthrough Therapy Designation designation for ulixacaltamide was granted after positive topline results from the Essential3 program, which included two Phase 3 studies.

Equity

The Breakthrough Therapy Designation designation for ulixacaltamide was granted after positive topline results from the Essential3 program, which included two Phase 3 studies.


Congress Asset Management Co. Makes New Investment in Praxis Precision Medicines, Inc. $PRAX

Congress Asset Management Co. acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the third quarter, according to its most recent 13F filing with the...

Praxis Precision Medicines (NASDAQ:PRAX) Hits New 52-Week High - What's Next?

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Time to Buy...

Assenagon Asset Management S.A. Has $21.72 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX

Assenagon Asset Management S.A. cut its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 32.2% in the 3rd quarter, according to its most recent Form 13F filing with the...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) has received an average recommendation of "Moderate Buy" from the seventeen ratings firms that are covering the firm, Marketbeat...

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

PRAX
Praxis Precision Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRAX News

PRAXPraxis Precision Medicines Inc